Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Goodwill (2017 - 2019)

Historic Goodwill for Aclaris Therapeutics (ACRS) over the last 3 years, with Q4 2019 value amounting to $18.5 million.

  • Aclaris Therapeutics' Goodwill changed 0.0% to $18.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was $18.5 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $18.5 million for FY2019, which is 0.0% changed from last year.
  • Aclaris Therapeutics' Goodwill amounted to $18.5 million in Q4 2019, which was down 0.0% from $18.5 million recorded in Q1 2019.
  • Over the past 5 years, Aclaris Therapeutics' Goodwill peaked at $18.5 million during Q3 2017, and registered a low of $18.5 million during Q3 2017.
  • For the 3-year period, Aclaris Therapeutics' Goodwill averaged around $18.5 million, with its median value being $18.5 million (2017).
  • Within the past 5 years, the most significant YoY rise in Aclaris Therapeutics' Goodwill was 0.0% (2018), while the steepest drop was 0.0% (2018).
  • Over the past 3 years, Aclaris Therapeutics' Goodwill (Quarter) stood at $18.5 million in 2017, then changed by 0.0% to $18.5 million in 2018, then changed by 0.0% to $18.5 million in 2019.
  • Its Goodwill stands at $18.5 million for Q4 2019, versus $18.5 million for Q1 2019 and $18.5 million for Q4 2018.